What the Research Evidence Actually Shows Across Peptide Categories

Let's look at the main categories people ask about.
GH-releasing peptides like CJC-1295, GHRP-2, GHRP-6, tesamorelin, and sermorelin work by stimulating the growth hormone secretagogue receptor. Studies consistently show they elevate growth hormone levels. The IGF-1 response, however, varies considerably based on age, dose, and individual factors. The most robust human data exists for tesamorelin in HIV-associated lipodystrophy, where it received FDA approval for that specific indication.
BPC-157 has generated significant interest in online communities. Preclinical data in rodents shows promising healing effects on the gastrointestinal tract, tendons, and central nervous system. The mechanistic studies suggest involvement of VEGF, nitric oxide, and growth hormone pathways. However, no large human randomized controlled trials had been completed as of early 2024. That's a significant gap between animal studies and human recommendations.
Thymosin Alpha-1 is FDA-approved for hepatitis B and as an immune adjuvant in certain cancer treatments. Off-label use in wellness settings is widespread. The evidence base outside those original approved indications is mixed, with limited high-quality studies supporting general immune "boosting" claims.
Epithalon has been studied primarily in Russian research for decades, with some data on telomere length. These studies have methodological limitations, and the findings haven't been replicated in large Western trials. The evidence remains preliminary.